ATLANTA, July 24, 2017 /PRNewswire/ --
Second Quarter Highlights:
- Revenues Increased Two Percent Year-over-Year to
$47.8 Million; Non-GAAP Revenues
Increased Four Percent Year-over-Year
- Gross Margins were 69 Percent
- GAAP Net Income was $3.2
Million, or $0.09 Per Fully
Diluted Common Share; Non-GAAP Net Income was
$4.0 Million, or $0.12 Per Fully Diluted Common Share
CryoLife, Inc. (NYSE: CRY), a leading medical device and
tissue processing company focused on cardiac surgery, announced
today its results for the second quarter and first half of
2017.
Pat Mackin, Chairman, President,
and Chief Executive Officer, said, "We had a solid second quarter
and exceeded our guidance despite facing certain headwinds in the
quarter. On-X, BioGlue and tissue processing all posted
revenue growth. This was highlighted by another positive
quarter for On-X, particularly in North
America where On-X revenue grew 19 percent excluding the OEM
business. In tissue processing, we delivered our second
consecutive quarter of double-digit growth in cardiac tissue.
During the quarter we also initiated the transition to direct sales
in Canada, Belgium, the
Netherlands and Luxembourg,
further expanding our direct operations in Europe. We are on track to achieve our 2017
financial guidance and remain confident our strategy will continue
to transform CryoLife into a higher growth, higher margin
company."
Revenues for the second quarter of 2017 increased two percent to
$47.8 million, compared to
$47.1 million for the second quarter
of 2016. The increase was primarily driven by increases in
tissue processing, BioGlue, On-X and TMR revenues, partially offset
by the absence of HeRO revenues. Non-GAAP revenues for the
second quarter of 2017 increased four percent compared to the
second quarter of 2016. A reconciliation of GAAP to non-GAAP
financial metrics is included as part of this press release.
Revenues for the first half of 2017 increased three percent to
$92.9 million, compared to
$90.1 million for the first half of
2016. The increase was primarily driven by increases in On-X,
tissue processing and BioGlue revenues, partially offset by the
absence of HeRO and ProCol revenues, and a decrease in TMR
revenues. Non-GAAP revenues for the first half of 2017
increased four percent compared to the first half of 2016. A
reconciliation of GAAP to non-GAAP financial metrics is included as
part of this press release.
GAAP net income for the second quarter of 2017 was $3.2 million, or $0.09 per fully diluted common share, compared to
net income of $2.3 million, or
$0.07 per fully diluted common share,
for the second quarter of 2016. Non-GAAP net income for the
second quarter of 2017 was $4.0
million, or $0.12 per fully
diluted common share, compared to non-GAAP net income of
$4.3 million, or $0.13 per fully diluted common share for the
second quarter of 2016.
GAAP net income for the first half of 2017 was $5.4 million, or $0.16 per fully diluted common share, compared to
net income of $4.9 million, or
$0.15 per fully diluted common share,
for the first half of 2016. Non-GAAP net income for the first
half of 2017 was $7.2 million, or
$0.21 per fully diluted common share,
compared to non-GAAP net income of $7.6
million, or $0.23 per fully
diluted common share for the first half of 2016.
With the exception of the income tax rate, the Company is
reiterating its full year 2017 financial guidance, as summarized
below, and expects revenues in the third quarter of 2017 to be
between $46.5 million and $47.5
million.
2017 Financial
Guidance Summary
|
Total
revenues
|
$188 Million - $192
Million
|
Product
revenues
|
Year-over-year
mid-single digits % non-GAAP
revenue increase
|
Tissue processing
revenues
|
Year-over-year
mid-single digits % revenue
increase
|
Gross
margins
|
Between 68% -
69%
|
R&D
expenses
|
$17.0 Million - $19.0
Million
|
Income tax
rate
|
Mid
10%
|
Non-GAAP income per
common share
|
$0.40 -
$0.43
|
All numbers in the table above are GAAP except where expressly
referenced as non-GAAP. The Company does not provide GAAP
income per common share on a forward-looking basis because the
Company is unable to predict with reasonable certainty business
development and acquisition-related expenses, purchase accounting
fair value adjustments, and any unusual gains and losses without
unreasonable effort. These items are uncertain, depend on
various factors, and could be material to results computed in
accordance with GAAP.
The Company's financial guidance for 2017 is subject to the
risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures.
Investors should consider this non-GAAP information in addition to,
and not as a substitute for, financial measures prepared in
accordance with U.S. GAAP. In addition, this non-GAAP
financial information may not be the same as similar measures
presented by other companies. The Company's non-GAAP revenues
include (as applicable) On-X revenues for the period in 2016 prior
to the closing of the acquisition and excludes revenues for the
HeRO Graft and ProCol product lines for 2016. The Company's
other non-GAAP results exclude (as applicable) business development
expenses; gain on sale of business components; amortization
expenses; and inventory basis step-up expense. The Company
believes that these non-GAAP presentations provide useful
information to investors regarding unusual non-operating
transactions and the operating expense structure of the Company's
existing and recently acquired operations, without regard to its
on-going efforts to acquire additional complementary products and
businesses and the transaction and integration expenses incurred in
connection with recently acquired and divested product lines.
The Company believes it is useful to exclude certain expenses
because such amounts in any specific period may not directly
correlate to the underlying performance of its business operations
or can vary significantly between periods as a result of factors
such as new acquisitions, or non-cash expense related to
amortization of previously acquired tangible and intangible assets.
The Company does, however, expect to incur similar types of
expenses in the future, and this non-GAAP financial information
should not be viewed as a statement or indication that these types
of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast
tomorrow at 8:00 a.m. Eastern Time to
discuss the results followed by a question and answer session
hosted by Mr. Mackin.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 8:00 a.m. A replay of the teleconference
will be available July 25 through July
31, and can be accessed by calling (toll free) 877-660-6853
or 201-612-7415. The conference number for the replay is
13665887.
The live webcast and replay can be accessed by going to the
Investor Relations section of the CryoLife website at
www.cryolife.com and selecting the heading Webcasts &
Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta,
Georgia, CryoLife is a leader in the manufacturing,
processing, and distribution of medical devices and implantable
tissues used in cardiac surgical procedures. CryoLife markets
and sells products in more than 80 countries worldwide. For
additional information about CryoLife, visit our website,
www.cryolife.com.
Statements made in this press release that look forward in
time or that express management's beliefs, expectations,
or hopes are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements reflect the views of management at the
time such statements are made. These statements include
those regarding our financial guidance for 2017 and our
ability to keep on track to achieve our 2017 financial guidance
and to continue to build CryoLife into a higher growth, higher
margin company. These
forward-looking statements are subject to a number of risks,
uncertainties, estimates, and assumptions that may cause actual
results to differ materially from current expectations. These
risks and uncertainties include that the expected benefits of
our focus on certain key initiatives may be incorrect or may not be
achieved; we may not achieve the growth in core products that we
expect; we may not continue to make progress at all or as quickly
as we would like on certain items that negatively impacted the
fourth quarter of 2016; we may not achieve the financial benefits
of moving to direct sales channels in Canada, Belgium, the
Netherlands, and Luxembourg
and expanding our direct sales operations in Europe; and our business development efforts
may not be successful. These risks and uncertainties include
the risk factors detailed in our Securities and Exchange Commission
filings, including our Form 10-K for the year ended December 31, 2016, and our subsequent filings
with the SEC. CryoLife does not undertake to update its
forward-looking statements.
CRYOLIFE, INC. AND
SUBSIDIARIES
Financial
Highlights
(In thousands,
except per share data)
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
June
30,
|
|
June
30,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
$
|
30,094
|
|
$
|
30,045
|
|
$
|
57,490
|
|
$
|
57,063
|
Preservation
services
|
|
17,724
|
|
|
17,038
|
|
|
35,387
|
|
|
33,036
|
Total
revenues
|
|
47,818
|
|
|
47,083
|
|
|
92,877
|
|
|
90,099
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products
and preservation services:
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
|
6,959
|
|
|
7,698
|
|
|
14,976
|
|
|
14,701
|
Preservation
services
|
|
7,954
|
|
|
9,084
|
|
|
15,484
|
|
|
17,476
|
Total cost of
products and
|
|
|
|
|
|
|
|
|
|
|
|
preservation
services
|
|
14,913
|
|
|
16,782
|
|
|
30,460
|
|
|
32,177
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
margin
|
|
32,905
|
|
|
30,301
|
|
|
62,417
|
|
|
57,922
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
General,
administrative, and marketing
|
|
23,389
|
|
|
22,436
|
|
|
46,260
|
|
|
48,710
|
Research and
development
|
|
4,728
|
|
|
3,279
|
|
|
8,821
|
|
|
5,888
|
Total operating
expenses
|
|
28,117
|
|
|
25,715
|
|
|
55,081
|
|
|
54,598
|
Gain
from sale of business components
|
|
--
|
|
|
--
|
|
|
--
|
|
|
(7,915)
|
Operating
income
|
|
4,788
|
|
|
4,586
|
|
|
7,336
|
|
|
11,239
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
834
|
|
|
797
|
|
|
1,635
|
|
|
1,514
|
Interest
income
|
|
(55)
|
|
|
(18)
|
|
|
(95)
|
|
|
(30)
|
Other (income),
net
|
|
(134)
|
|
|
(58)
|
|
|
(91)
|
|
|
(167)
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before
income taxes
|
|
4,143
|
|
|
3,865
|
|
|
5,887
|
|
|
9,922
|
Income tax
expense
|
|
980
|
|
|
1,518
|
|
|
501
|
|
|
5,034
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
$
|
3,163
|
|
$
|
2,347
|
|
$
|
5,386
|
|
$
|
4,888
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per common
share:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
$
|
0.09
|
|
$
|
0.07
|
|
$
|
0.16
|
|
$
|
0.15
|
Diluted
|
$
|
0.09
|
|
$
|
0.07
|
|
$
|
0.16
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
32,664
|
|
|
32,010
|
|
|
32,552
|
|
|
31,519
|
Diluted
|
|
33,814
|
|
|
32,764
|
|
|
33,739
|
|
|
32,270
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRYOLIFE, INC. AND
SUBSIDIARIES
Financial
Highlights
(In
thousands)
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
June
30,
|
|
June
30,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Products:
|
|
|
|
|
|
|
|
|
|
|
|
BioGlue and
BioFoam
|
$
|
16,683
|
|
$
|
16,187
|
|
$
|
32,364
|
|
$
|
31,503
|
On-X
|
|
9,862
|
|
|
9,554
|
|
|
18,722
|
|
|
16,269
|
CardioGenesis cardiac
laser therapy
|
|
2,056
|
|
|
1,860
|
|
|
3,641
|
|
|
3,844
|
PerClot
|
|
936
|
|
|
1,042
|
|
|
1,755
|
|
|
2,033
|
PhotoFix
|
|
557
|
|
|
490
|
|
|
1,008
|
|
|
871
|
HeRO Graft
|
|
--
|
|
|
912
|
|
|
--
|
|
|
2,325
|
ProCol
|
|
--
|
|
|
--
|
|
|
--
|
|
|
218
|
Total products
|
|
30,094
|
|
|
30,045
|
|
|
57,490
|
|
|
57,063
|
|
|
|
|
|
|
|
|
|
|
|
|
Preservation
services:
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac
tissue
|
|
8,477
|
|
|
7,548
|
|
|
15,979
|
|
|
13,976
|
Vascular
tissue
|
|
9,247
|
|
|
9,490
|
|
|
19,408
|
|
|
19,060
|
Total preservation
services
|
|
17,724
|
|
|
17,038
|
|
|
35,387
|
|
|
33,036
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenues
|
$
|
47,818
|
|
$
|
47,083
|
|
$
|
92,877
|
|
$
|
90,099
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
|
34,712
|
|
$
|
34,198
|
|
$
|
68,246
|
|
$
|
66,436
|
International
|
|
13,106
|
|
|
12,885
|
|
|
24,631
|
|
|
23,663
|
Total
revenues
|
$
|
47,818
|
|
$
|
47,083
|
|
$
|
92,877
|
|
$
|
90,099
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June
30,
|
|
December
31,
|
|
|
2017
|
|
2016
|
|
|
|
|
|
|
|
|
Cash, cash
equivalents, and restricted securities
|
$
|
53,248
|
|
$
|
57,341
|
|
Total current
assets
|
|
152,211
|
|
|
147,233
|
|
Total
assets
|
|
322,221
|
|
|
316,140
|
|
Total current
liabilities
|
|
25,771
|
|
|
30,102
|
|
Total
liabilities
|
|
103,160
|
|
|
107,157
|
|
Shareholders'
equity
|
|
219,061
|
|
|
208,983
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRYOLIFE, INC. AND
SUBSIDIARIES
Reconciliation of
GAAP to Non-GAAP
Net Income and
Diluted Income per Common Share
(In thousands,
except per share data)
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
June
30,
|
|
June
30,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
GAAP:
|
|
|
|
|
|
|
|
|
|
|
|
Income before
income taxes
|
$
|
4,143
|
|
$
|
3,865
|
|
$
|
5,887
|
|
$
|
9,922
|
Income tax
expense
|
|
980
|
|
|
1,518
|
|
|
501
|
|
|
5,034
|
Net
income
|
$
|
3,163
|
|
$
|
2,347
|
|
$
|
5,386
|
|
$
|
4,888
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per
common share:
|
$
|
0.09
|
|
$
|
0.07
|
|
$
|
0.16
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
weighted-average common
|
|
|
|
|
|
|
|
|
|
|
|
shares
outstanding
|
|
33,814
|
|
|
32,764
|
|
|
33,739
|
|
|
32,270
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
of income before income
|
|
|
|
|
|
|
|
|
|
|
|
taxes, GAAP to
net income, non-GAAP:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before
income taxes, GAAP
|
$
|
4,143
|
|
$
|
3,865
|
|
$
|
5,887
|
|
$
|
9,922
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
Business development
expenses
|
|
1,094
|
|
|
1,067
|
|
|
1,382
|
|
|
6,635
|
Gain on sale of
business components
|
|
--
|
|
|
--
|
|
|
--
|
|
|
(7,915)
|
Amortization
expense
|
|
1,141
|
|
|
1,156
|
|
|
2,283
|
|
|
2,118
|
Acquisition inventory
basis step-up expense
|
|
63
|
|
|
902
|
|
|
2,112
|
|
|
1,467
|
Income before
income taxes, non-GAAP
|
|
6,441
|
|
|
6,990
|
|
|
11,664
|
|
|
12,227
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
calculated at 38% normalized
|
|
|
|
|
|
|
|
|
|
|
|
tax rate
|
|
2,448
|
|
|
2,656
|
|
|
4,432
|
|
|
4,646
|
Net income,
non-GAAP
|
$
|
3,993
|
|
$
|
4,334
|
|
$
|
7,232
|
|
$
|
7,581
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
of diluted income per
|
|
|
|
|
|
|
|
|
|
|
|
common share,
GAAP to diluted income per
|
|
|
|
|
|
|
|
|
|
|
|
common share,
non-GAAP:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per
common share, GAAP:
|
$
|
0.09
|
|
$
|
0.07
|
|
$
|
0.16
|
|
$
|
0.15
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
Business development
expenses
|
|
0.03
|
|
|
0.03
|
|
|
0.04
|
|
|
0.20
|
Gain on sale of
business components
|
|
--
|
|
|
--
|
|
|
--
|
|
|
(0.24)
|
Amortization
expense
|
|
0.03
|
|
|
0.03
|
|
|
0.07
|
|
|
0.06
|
Acquisition inventory
basis step-up expense
|
|
--
|
|
|
0.03
|
|
|
0.06
|
|
|
0.04
|
Tax effect of non-GAAP
adjustments
|
|
(0.02)
|
|
|
(0.03)
|
|
|
(0.07)
|
|
|
(0.02)
|
Effect of 38%
normalized tax rate
|
|
(0.01)
|
|
|
--
|
|
|
(0.05)
|
|
|
0.04
|
Diluted income per
common share,
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP:
|
$
|
0.12
|
|
$
|
0.13
|
|
$
|
0.21
|
|
$
|
0.23
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
weighted-average common
|
|
|
|
|
|
|
|
|
|
|
|
shares
outstanding
|
|
33,814
|
|
|
32,764
|
|
|
33,739
|
|
|
32,270
|
|
|
|
|
|
|
|
|
|
|
|
|
CRYOLIFE, INC. AND
SUBSIDIARIES
Reconciliation of
GAAP to Non-GAAP
Revenues; Gross
Margin; General, Administrative, and Marketing
(In thousands,
except per share data)
|
|
|
|
Three Months Ended
|
|
Six Months
Ended
|
|
June
30,
|
|
June
30,
|
|
2017
|
|
2016
|
Growth
Rate
|
|
2017
|
|
2016
|
Growth
Rate
|
Reconciliation
of total revenues, GAAP
|
|
|
|
|
|
|
|
|
|
|
|
|
|
to total
revenues, non-GAAP:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues,
GAAP
|
$
|
47,818
|
|
$
|
47,083
|
2%
|
|
$
|
92,877
|
|
$
|
90,099
|
3%
|
Plus: On-X pre
acquisition revenues
|
|
--
|
|
|
--
|
|
|
|
--
|
|
|
1,627
|
|
Less: HeRO
revenues
|
|
--
|
|
|
(912)
|
|
|
|
--
|
|
|
(2,325)
|
|
Less: ProCol
revenues
|
|
--
|
|
|
--
|
|
|
|
--
|
|
|
(218)
|
|
Total revenues,
non-GAAP
|
$
|
47,818
|
|
$
|
46,171
|
4%
|
|
$
|
92,877
|
|
$
|
89,183
|
4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
Six Months
Ended
|
|
|
June
30,
|
|
|
June
30,
|
|
|
2017
|
|
2016
|
|
|
2017
|
|
2016
|
|
Reconciliation
of gross margin %,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP to gross
margin %,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues,
GAAP
|
$
|
47,818
|
|
$
|
47,083
|
|
|
$
|
92,877
|
|
$
|
90,099
|
|
Gross margin,
GAAP
|
$
|
32,905
|
|
$
|
30,301
|
|
|
$
|
62,417
|
|
$
|
57,922
|
|
Gross margin %,
GAAP
|
|
69%
|
|
|
64%
|
|
|
|
67%
|
|
|
64%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin,
GAAP
|
$
|
32,905
|
|
$
|
30,301
|
|
|
$
|
62,417
|
|
$
|
57,922
|
|
Plus: Acquisition
inventory basis step-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
up expense
|
|
63
|
|
|
902
|
|
|
|
2,112
|
|
|
1,467
|
|
Gross margin,
non-GAAP
|
$
|
32,968
|
|
$
|
31,203
|
|
|
$
|
64,529
|
|
$
|
59,389
|
|
Gross margin %,
non-GAAP
|
|
69%
|
|
|
66%
|
|
|
|
69%
|
|
|
66%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
Six Months
Ended
|
|
|
June
30,
|
|
|
June
30,
|
|
|
2017
|
|
2016
|
|
|
2017
|
|
2016
|
|
Reconciliation
of general,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
administrative,
and marketing,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expense, GAAP to
general,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
administrative,
and marketing,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expense,
non-GAAP
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General,
administrative, and marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expense,
GAAP
|
$
|
23,389
|
|
$
|
22,436
|
|
|
$
|
46,260
|
|
$
|
48,710
|
|
Less: Business
development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expenses
|
|
(1,094)
|
|
|
(1,067)
|
|
|
|
(1,382)
|
|
|
(6,635)
|
|
General,
administrative, and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
marketing
expense,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP
|
$
|
22,295
|
|
$
|
21,369
|
|
|
$
|
44,878
|
|
$
|
42,075
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contacts:
|
|
|
|
CryoLife
D. Ashley
Lee
Executive Vice
President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355
|
The Ruth
Group
Zack Kubow
646-536-7020
zkubow@theruthgroup.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/cryolife-reports-second-quarter-2017-financial-results-300493045.html
SOURCE CryoLife, Inc.